Axsome Therapeutics has built a portfolio of differentiated product candidates that address areas of high unmet medical needs.
Our pipeline includes five differentiated clinical-stage central nervous system (CNS) therapies targeting significant and growing markets.
Sunosi
EDS
AXS-05
Major Depressive Disorder: Breakthrough Therapy Designation
Alzheimer’s Disease Agitation: Breakthrough Therapy Designation
Smoking Cessation
AXS-07
Migraine
AXS-12
Narcolepsy: Orphan Therapy Designation
AXS-14
Fibromyalgia
Abbreviations: CNS = Central Nervous System; MOA = Mechanism of Action; NMDA = N-Methyl-D-aspartate; COX-2 = Cyclooxygenase-2; 5-HT = 5-Hydroxytryptamine; NE = Norepinephrine
Please refer to the full Prescribing Information for Sunosi.
The investigational product candidates on this page are not approved by the FDA and the safety and effectiveness has not been established.
Expanded Access Policy